Leucine-rich repeat kinase 2 (LRRK2) has gone, in a little over 2 decades, from a novel gene linked to cases of Parkinson’s disease (PD) in one family to being the main actionable target for PD therapeutics, with several clinical trials targeting it currently underway. This evidence concerns the gene LRRK2 and Parkinson disease.